Stockscreener 앱 받기
20.31
2.17%
-0.45
시간 외 거래:
20.31
전일 마감가:
$20.76
열려 있는:
$20.31
하루 거래량:
2.38M
Relative Volume:
11.68
시가총액:
$710.82M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.43%
1개월 성능:
-8.51%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$19.84
$21.58
1주일 범위
$19.84
$23.57
52주 변동 폭
$18.20
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
ORKA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
20.31 | 710.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Franklin Resources Inc. Takes $17.66 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright bullish on Oruka stock after early clinical success for ORKA-001 - Investing.com UK
Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 - Yahoo Finance
Oruka Therapeutics enters exclusive licensing deal with Paragon - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 4.7%What's Next? - MarketBeat
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - The Manila Times
Oruka Therapeutics Announces First Participants Dosed in - GlobeNewswire
Oruka Therapeutics Launches Phase 1 Trial of Revolutionary Long-Acting Psoriasis Treatment ORKA-001 - StockTitan
Wellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Wellington Management Group LLP Takes $2.01 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Oruka Therapeutics to Join Prestigious Nasdaq Biotechnology Index in Major Milestone - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume IncreaseShould You Buy? - MarketBeat
The Manufacturers Life Insurance Company Invests $1.04 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Frazier Life Sciences Management L.P. Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 482,330 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
RTW Investments LP Takes $45.36 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Redmile Group LLC Acquires Shares of 411,728 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Fmr LLC Buys Shares of 4,682,300 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics: Strong Q3 and Strategic Advances - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages - Defense World
Braidwell LP Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.4%Here's Why - MarketBeat
Great Point Partners LLC Takes $12.61 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for ORKA - MarketBeat
Oruka stock stays Buy-rated as H.C. Wainwright emphasizes annual dosing potential for ORKA-001 - Investing.com UK
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Fairmount Funds Management LLC's Strategic Acquisition in Oruka Therapeutics Inc - GuruFocus.com
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire
Oruka Therapeutics gains approval for preferred stock conversion - Investing.com
Oruka Therapeutics adjusts financials post-merger By Investing.com - Investing.com Canada
Oruka Therapeutics adjusts financials post-merger - Investing.com
JANUS HENDERSON GROUP PLC Acquires New Stake in Oruka Therapeuti - GuruFocus.com
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Raises $475M, Accelerates Clinical Timeline for Key Drug Programs | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan
Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha
Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada
Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks
Anti-IL-23 antibody demonstrates potential for long-term dosing - BioWorld Online
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
2.88%
2.65%
자본화:
|
볼륨(24시간):